Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia
- PMID: 12637616
- DOI: 10.1056/NEJMe030009
Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia
Comment on
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457. N Engl J Med. 2003. PMID: 12637609 Clinical Trial.
Similar articles
-
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.Bone Marrow Transplant. 2004 Nov;34(9):827-8. doi: 10.1038/sj.bmt.1704687. Bone Marrow Transplant. 2004. PMID: 15334052 No abstract available.
-
[Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies].Bull Cancer. 2005 Jan;92(1):75-82. Bull Cancer. 2005. PMID: 15689327 Review. French.
-
Imatinib mesylate.Rev Gastroenterol Disord. 2002;2(2):75-86. Rev Gastroenterol Disord. 2002. PMID: 12122963 Review.
-
[Treatment strategies for chronic myeloid leukemia].Rinsho Ketsueki. 2005 Jan;46(1):1-6. Rinsho Ketsueki. 2005. PMID: 16708910 Japanese. No abstract available.
-
Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.Clin Adv Hematol Oncol. 2003 Jul;1(7):398-400. Clin Adv Hematol Oncol. 2003. PMID: 16258420 No abstract available.
Cited by
-
Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells.Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):525-537. doi: 10.3724/abbs.2023280. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38414349 Free PMC article.
-
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy.Semin Cancer Biol. 2022 Nov;86(Pt 2):269-279. doi: 10.1016/j.semcancer.2022.07.001. Epub 2022 Jul 4. Semin Cancer Biol. 2022. PMID: 35798235 Free PMC article. Review.
-
Genetic fusions favor tumorigenesis through degron loss in oncogenes.Nat Commun. 2021 Nov 18;12(1):6704. doi: 10.1038/s41467-021-26871-y. Nat Commun. 2021. PMID: 34795215 Free PMC article.
-
Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan.Pharmacoecon Open. 2022 Mar;6(2):137-145. doi: 10.1007/s41669-021-00293-4. Epub 2021 Nov 13. Pharmacoecon Open. 2022. PMID: 34773599 Free PMC article.
-
A Pilot Study on Probing of Imatinib Induced Platelet Dysfunction in Patients with Chronic Myeloid Leukemia-Chronic Phase and Absence of Associated Bleeding Manifestation: Trying to Solve an Enigma.Indian J Hematol Blood Transfus. 2021 Jan;37(1):162-166. doi: 10.1007/s12288-020-01376-8. Epub 2020 Nov 13. Indian J Hematol Blood Transfus. 2021. PMID: 33707851 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical